Los Angeles Capital Management LLC Purchases Shares of 2,057 Repligen Co. (NASDAQ:RGEN)

Los Angeles Capital Management LLC acquired a new stake in Repligen Co. (NASDAQ:RGEN) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 2,057 shares of the biotechnology company’s stock, valued at approximately $306,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in RGEN. Russell Investments Group Ltd. lifted its stake in shares of Repligen by 5.2% in the 1st quarter. Russell Investments Group Ltd. now owns 35,134 shares of the biotechnology company’s stock valued at $6,463,000 after purchasing an additional 1,746 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in Repligen by 30.2% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 28,883 shares of the biotechnology company’s stock worth $5,312,000 after buying an additional 6,705 shares during the period. Vanguard Group Inc. raised its stake in Repligen by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 5,100,013 shares of the biotechnology company’s stock worth $937,994,000 after buying an additional 21,719 shares during the period. Cynosure Group LLC acquired a new position in Repligen during the 1st quarter worth approximately $304,000. Finally, O Shaughnessy Asset Management LLC raised its stake in Repligen by 6.9% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 1,924 shares of the biotechnology company’s stock worth $354,000 after buying an additional 125 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $124.73 on Monday. The stock has a fifty day simple moving average of $141.09 and a two-hundred day simple moving average of $144.34. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $211.13. The firm has a market cap of $6.99 billion, a price-to-earnings ratio of -337.10, a price-to-earnings-growth ratio of 3.43 and a beta of 0.96. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a positive return on equity of 3.92% and a negative net margin of 3.36%. The business had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same period in the prior year, the company earned $0.23 earnings per share. Repligen’s revenue was up 9.7% compared to the same quarter last year. Analysts anticipate that Repligen Co. will post 1.52 earnings per share for the current year.

Insider Transactions at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now owns 139,840 shares in the company, valued at approximately $20,328,540.80. This trade represents a 13.70 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 1.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on RGEN shares. Benchmark reaffirmed a “hold” rating on shares of Repligen in a research note on Monday, August 5th. Wells Fargo & Company started coverage on Repligen in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price objective for the company. Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a research note on Thursday, September 26th. Stephens reissued an “overweight” rating and issued a $170.00 price objective on shares of Repligen in a research note on Tuesday, July 30th. Finally, StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a research note on Wednesday, November 13th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $190.25.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.